Literature DB >> 9523354

Clinical significance of serum P53 antibody in patients with gastric cancer.

G Shiota1, M Ishida, N Noguchi, Y Takano, K Oyama, M Okubo, S Katayama, K Harada, K Hori, K Ashida, Y Kishimoto, A Hosoda, T Suou, H Ito, H Kawasaki.   

Abstract

The presence of serum p53 antibody has been reported to have prognostic significance in patients with breast and ovarian cancers. In order to clarify clinical and prognostic significance of p53 antibody in serum, we measured p53 antibody in patients with gastric cancer. Twenty-five patients with gastric cancer were examined as well as 9 patients with gastric polyp as controls. Eight of 25 patients (32%) with gastric cancer were positive for p53 antibody, while no patients with gastric polyp were positive in gastric polyp group (p < 0.05). The presence of p53 antibody was significantly associated with histology, liver metastasis and stage classification in gastric cancer (p < 0.05, respectively). Presence of liver metastasis, type of histology and presence of p53 antibody are independent prognostic factors (p < 0.05, respectively). The overall survival in patients with p53 antibody was significantly shorter survival than for those without antibody (p < 0.05%). These data suggest that p53 antibody serves as one of the prognostic factors in gastric cancer.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9523354

Source DB:  PubMed          Journal:  Res Commun Mol Pathol Pharmacol        ISSN: 1078-0297


  6 in total

1.  Titration of serum p53 antibodies in patients with gastric cancer: a single-institute study of 40 patients.

Authors:  Keiji Shimizu; Yuji Ueda; Hisakazu Yamagishi
Journal:  Gastric Cancer       Date:  2005       Impact factor: 7.370

2.  Negative conversion of high serum p53 antibody titers in a patient with gastric cancer at 31 months after surgery.

Authors:  Kenji Murayama; Tatsuki Nanami; Takashi Suzuki; Yoko Oshima; Satoshi Yajima; Tetsuo Nemoto; Hideaki Shimada
Journal:  Clin J Gastroenterol       Date:  2017-05-24

Review 3.  Emerging blood-based biomarkers for detection of gastric cancer.

Authors:  Zane Kalniņa; Irēna Meistere; Ilze Kikuste; Ivars Tolmanis; Pawel Zayakin; Aija Linē
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

4.  Panel of autoantibodies against multiple tumor-associated antigens for detecting gastric cancer.

Authors:  Isamu Hoshino; Matsuo Nagata; Nobuhiro Takiguchi; Yoshihiro Nabeya; Atsushi Ikeda; Sana Yokoi; Akiko Kuwajima; Masatoshi Tagawa; Kazuyuki Matsushita; Yajima Satoshi; Shimada Hideaki
Journal:  Cancer Sci       Date:  2017-03       Impact factor: 6.716

Review 5.  The Multifaceted Roles of B Cells in Solid Tumors: Emerging Treatment Opportunities.

Authors:  Nicole J Flynn; Rajasekharan Somasundaram; Kimberly M Arnold; Jennifer Sims-Mourtada
Journal:  Target Oncol       Date:  2017-04       Impact factor: 4.864

Review 6.  Autoimmunity and Gastric Cancer.

Authors:  Nicola Bizzaro; Antonio Antico; Danilo Villalta
Journal:  Int J Mol Sci       Date:  2018-01-26       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.